Literature DB >> 8210831

How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma.

C Com-Nougue1, C Rodary, C Patte.   

Abstract

Interest in equivalence trials has been increasing for many years, though the methodology which has been developed for such trials is mainly for uncensored data. In cancer research we are more often concerned with survival. In an efficacy trial, the null hypothesis specifies equality of the two survival distributions, but in an equivalence trial, a null hypothesis of inequivalence H0 has to be tested. The usual logrank test has to be modified to test whether the true value r of the ratio of hazard rates in two treatment groups is at least equal to a limit value r0. If prognostic factors have to be taken into account, the Cox model provides tests of Ho, and a useful confidence interval for the adjusted relative derived from the regression parameter for the treatment indicator. An equivalence trial of maintenance therapy was carried out in children with B non-Hodgkin lymphoma, and serves as an illustration.

Entities:  

Mesh:

Year:  1993        PMID: 8210831     DOI: 10.1002/sim.4780121407

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Methods for equivalence and noninferiority testing.

Authors:  Gisela Tunes da Silva; Brent R Logan; John P Klein
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

2.  Tests for equivalence of two survival functions: Alternative to the tests under proportional hazards.

Authors:  Elvis E Martinez; Debajyoti Sinha; Wenting Wang; Stuart R Lipsitz; Richard J Chappell
Journal:  Stat Methods Med Res       Date:  2016-07-11       Impact factor: 3.021

3.  Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.

Authors:  J-L Lefebvre; G Andry; D Chevalier; B Luboinski; L Collette; L Traissac; D de Raucourt; J A Langendijk
Journal:  Ann Oncol       Date:  2012-04-06       Impact factor: 32.976

4.  Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time.

Authors:  Milind A Phadnis; Matthew S Mayo
Journal:  J Appl Stat       Date:  2020-04-24       Impact factor: 1.416

5.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

Review 6.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.

Authors:  Sabine Steiner; Andrej Schmidt; Thomas Zeller; Gunnar Tepe; Marcus Thieme; Lars Maiwald; Henrik Schröder; Wulf Euringer; Matthias Ulrich; Klaus Brechtel; Steffen Brucks; Erwin Blessing; Johannes Schuster; Ralf Langhoff; Sebastian Schellong; Norbert Weiss; Dierk Scheinert
Journal:  Eur Heart J       Date:  2020-07-14       Impact factor: 29.983

8.  Assessing the non-inferiority of prosthesis constructs used in hip replacement using data from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man: a benchmarking study.

Authors:  Kevin C Deere; Michael R Whitehouse; Martyn Porter; Ashley W Blom; Adrian Sayers
Journal:  BMJ Open       Date:  2019-04-29       Impact factor: 2.692

9.  Assessing the non-inferiority of prosthesis constructs used in total and unicondylar knee replacements using data from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man: a benchmarking study.

Authors:  Kevin C Deere; Michael R Whitehouse; Martyn Porter; Ashley W Blom; Adrian Sayers
Journal:  BMJ Open       Date:  2019-04-29       Impact factor: 2.692

Review 10.  Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges.

Authors:  Prabin Dahal; Julie A Simpson; Grant Dorsey; Philippe J Guérin; Ric N Price; Kasia Stepniewska
Journal:  Malar J       Date:  2017-10-26       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.